Computational Fragment-Based Drug Design

[1]  Richard J. Hall,et al.  Docking performance of fragments and druglike compounds. , 2011, Journal of medicinal chemistry.

[2]  Brian Pease,et al.  Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography† , 2009, Journal of medicinal chemistry.

[3]  Rommie E. Amaro,et al.  AutoGrow: A Novel Algorithm for Protein Inhibitor Design , 2009, Chemical biology & drug design.

[4]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[5]  O. Fjellström,et al.  Creating Novel Activated Factor XI Inhibitors through Fragment Based Lead Generation and Structure Aided Drug Design , 2015, PloS one.

[6]  S. J. Campbell,et al.  Ligand binding: functional site location, similarity and docking. , 2003, Current opinion in structural biology.

[7]  Susan M. Boyd,et al.  Fragment library design: efficiently hunting drugs in chemical space. , 2010, Drug discovery today. Technologies.

[8]  David Jou,et al.  Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). , 2011, Journal of medicinal chemistry.

[9]  Matthias Rarey,et al.  FlexNovo: Structure‐Based Searching in Large Fragment Spaces , 2006, ChemMedChem.

[10]  P M Dean,et al.  Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[11]  Matthias Rarey,et al.  Similarity searching in large combinatorial chemistry spaces , 2001, J. Comput. Aided Mol. Des..

[12]  Markus Hartenfeller,et al.  De novo drug design. , 2010, Methods in molecular biology.

[13]  Johann Gasteiger,et al.  Structure and reaction based evaluation of synthetic accessibility , 2007, J. Comput. Aided Mol. Des..

[14]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[15]  Holger Claussen,et al.  Searching Fragment Spaces with Feature Trees , 2009, J. Chem. Inf. Model..

[16]  Wendy A. Warr.  Fragment-based drug discovery: what really works. An interview with Sandy Farmer of Boehringer Ingelheim , 2011, J. Comput. Aided Mol. Des..

[17]  P. Clemons,et al.  Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.

[18]  Zhihai Liu,et al.  Evaluation of the performance of four molecular docking programs on a diverse set of protein‐ligand complexes , 2010, J. Comput. Chem..

[19]  Stefan Wetzel,et al.  Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.

[20]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[21]  Robert J. Jilek,et al.  Topomers: A Validated Protocol for Their Self-Consistent Generation , 2004, J. Chem. Inf. Model..

[22]  Jürgen Bajorath,et al.  Chemical Database Mining through Entropy-Based Molecular Similarity Assessment of Randomly Generated Structural Fragment Populations , 2007, J. Chem. Inf. Model..

[23]  Naoki Tanaka,et al.  Small-World Phenomena in Chemical Library Networks: Application to Fragment-Based Drug Discovery , 2009, J. Chem. Inf. Model..

[24]  Markus Wagener,et al.  A flexible approach to induced fit docking. , 2007, Journal of medicinal chemistry.

[25]  Eric Vangrevelinghe,et al.  Computational Approaches for Fragment Optimization , 2007 .

[26]  Luca Maria Gambardella,et al.  Ant Algorithms for Discrete Optimization , 1999, Artificial Life.

[27]  Mark Whittaker,et al.  The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..

[28]  Tingjun Hou,et al.  Drug and Drug Candidate Building Block Analysis , 2010, J. Chem. Inf. Model..

[29]  Jürgen Bajorath,et al.  Mining of Randomly Generated Molecular Fragment Populations Uncovers Activity-Specific Fragment Hierarchies , 2007, J. Chem. Inf. Model..

[30]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[31]  L. Mueller,et al.  Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening. , 2015, Journal of medicinal chemistry.

[32]  Adriaan P. IJzerman,et al.  Computational Approaches to Fragment and Substructure Discovery and Evaluation , 2008 .

[33]  Qiyue Hu,et al.  Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery , 2011, J. Comput. Aided Mol. Des..

[34]  Dragos Horvath,et al.  Fragment-based drug design: computational & experimental state of the art. , 2011, Combinatorial chemistry & high throughput screening.

[35]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[36]  Peter Güntert,et al.  Structure-guided fragment-based in silico drug design of dengue protease inhibitors , 2011, J. Comput. Aided Mol. Des..

[37]  D. Ringe,et al.  Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.

[38]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[39]  Philip M. Dean,et al.  A validation study on the practical use of automated de novo design , 2002, J. Comput. Aided Mol. Des..

[40]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[41]  Matthew Clark,et al.  Grand Canonical Monte Carlo Simulation of Ligand-Protein Binding , 2006, J. Chem. Inf. Model..

[42]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[43]  E. Shakhnovich,et al.  SMoG: de Novo Design Method Based on Simple, Fast, and Accurate Free Energy Estimates. 1. Methodology and Supporting Evidence , 1996 .

[44]  Roderick E Hubbard,et al.  Informatics and modeling challenges in fragment-based drug discovery. , 2007, Current opinion in drug discovery & development.

[45]  Amedeo Caflisch,et al.  Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization , 2008, J. Chem. Inf. Model..

[46]  R. Griffey,et al.  SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. , 2002, Journal of medicinal chemistry.

[47]  Nathan Brown,et al.  Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.

[48]  Zhang Wannian,et al.  Constructing virtual combinatorial fragment libraries based upon MDL Drug Data Report database , 2007 .

[49]  M. Murcko,et al.  CONCERTS: dynamic connection of fragments as an approach to de novo ligand design. , 1996, Journal of medicinal chemistry.

[50]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[51]  Collin M. Stultz,et al.  The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design , 2009, J. Comput. Aided Mol. Des..

[52]  Gregg Siegal,et al.  Application of Fragment-Based Drug Discovery to Membrane Proteins: Identification of Ligands of the Integral Membrane Enzyme DsbB , 2015 .

[53]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[54]  Harald Mauser,et al.  Chemical Fragment Spaces for de novo Design , 2007, J. Chem. Inf. Model..

[55]  Matthew Clark,et al.  Fragment-Based Prediction of the Clinical Occurrence of Long QT Syndrome and Torsade de Pointes , 2009, J. Chem. Inf. Model..

[56]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[57]  Luhua Lai,et al.  LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .

[58]  Michal Vieth,et al.  Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.

[59]  Brian K Shoichet,et al.  Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.

[60]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[61]  Phillip Gribbon,et al.  High-throughput drug discovery: what can we expect from HTS? , 2005, Drug discovery today.

[62]  Denise G. Teotico,et al.  Docking for fragment inhibitors of AmpC β-lactamase , 2009, Proceedings of the National Academy of Sciences.

[63]  C. Lepre,et al.  Fragment-based drug discovery using the SHAPES method , 2007, Expert opinion on drug discovery.

[64]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[65]  Adriaan P. IJzerman,et al.  Complementarity between in Silico and Biophysical Screening Approaches in Fragment-Based Lead Discovery against the A2A Adenosine Receptor , 2013, J. Chem. Inf. Model..

[66]  Constantinos S. Pattichis,et al.  De Novo Drug Design Using Multiobjective Evolutionary Graphs , 2009, J. Chem. Inf. Model..

[67]  Paul Bamborough,et al.  Selectivity of kinase inhibitor fragments. , 2011, Journal of medicinal chemistry.

[68]  U Helena Danielson,et al.  Fragment library screening and lead characterization using SPR biosensors. , 2009, Current topics in medicinal chemistry.

[69]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[70]  Holger Claussen,et al.  Second-generation de novo design: a view from a medicinal chemist perspective , 2009, J. Comput. Aided Mol. Des..

[71]  Ashutosh Kumar,et al.  Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge , 2012, Journal of Computer-Aided Molecular Design.

[72]  W. Howe,et al.  Computer design of bioactive molecules: A method for receptor‐based de novo ligand design , 1991, Proteins.

[73]  Ian A. Watson,et al.  Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.

[74]  Dong Chen,et al.  Factor XI: hemostasis, thrombosis, and antithrombosis. , 2012, Thrombosis research.

[75]  Gisbert Schneider,et al.  Properties and Architecture of Drugs and Natural Products Revisited , 2007 .

[76]  Haruki Nakamura,et al.  In Silico Fragment Screening by Replica Generation (FSRG) Method for Fragment-Based Drug Design , 2009, J. Chem. Inf. Model..

[77]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[78]  Woody Sherman,et al.  Computational approaches for fragment-based and de novo design. , 2010, Current topics in medicinal chemistry.

[79]  M. Hutter,et al.  In silico prediction of drug properties. , 2009, Current medicinal chemistry.

[80]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[81]  Petra Schneider,et al.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..

[82]  Roderick E. Hubbard,et al.  Design of a Fragment Library that maximally represents available chemical space , 2011, J. Comput. Aided Mol. Des..

[83]  Amedeo Caflisch,et al.  Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. , 2009, Journal of medicinal chemistry.

[84]  X. Barril,et al.  Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. , 2009, Journal of medicinal chemistry.

[85]  Chenglong Li,et al.  Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein , 2010, J. Comput. Chem..

[86]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[87]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[88]  Paul A. Bartlett,et al.  CAVEAT: A program to facilitate the design of organic molecules , 1994, J. Comput. Aided Mol. Des..

[89]  M. Murcko,et al.  GroupBuild: a fragment-based method for de novo drug design. , 1993, Journal of medicinal chemistry.

[90]  B. Shoichet,et al.  Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.

[91]  Hans-Joachim Böhm,et al.  On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..

[92]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[93]  Robert J. Jilek,et al.  AllChem: generating and searching 1020 synthetically accessible structures , 2007, J. Comput. Aided Mol. Des..

[94]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[95]  R. Law.  Tetrabromobisphenol A: investigating the worst-case scenario. , 2009, Marine pollution bulletin.

[96]  Brian K. Shoichet,et al.  Increasing Chemical Space Coverage by Combining Empirical and Computational Fragment Screens , 2014, ACS chemical biology.

[97]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[98]  Thomas Bäck,et al.  Mining a Chemical Database for Fragment Co-occurrence: Discovery of "Chemical Clichés" , 2006, J. Chem. Inf. Model..

[99]  A. Caflisch,et al.  Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking. , 2014, Bioorganic & medicinal chemistry letters.

[100]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[101]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[102]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[103]  H. M. Vinkers,et al.  SYNOPSIS: SYNthesize and OPtimize System in Silico. , 2003, Journal of medicinal chemistry.

[104]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[105]  Christian Lemmen,et al.  Similarity searching and scaffold hopping in synthetically accessible combinatorial chemistry spaces. , 2008, Journal of medicinal chemistry.

[106]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[107]  Jürgen Bajorath,et al.  Assessment of Molecular Similarity from the Analysis of Randomly Generated Structural Fragment Populations , 2006, J. Chem. Inf. Model..

[108]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[109]  Hugo O Villar,et al.  Ring systems in mutagenicity databases. , 2005, Journal of medicinal chemistry.

[110]  Jens Meiler,et al.  ROSETTALIGAND: Protein–small molecule docking with full side‐chain flexibility , 2006, Proteins.

[111]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[112]  Hongming Wang,et al.  Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide , 2009, J. Comput. Aided Mol. Des..

[113]  Márton Vass,et al.  Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. , 2014, European journal of medicinal chemistry.

[114]  G. Klebe,et al.  Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design. , 2002, Farmaco.

[115]  L. Mario Amzel,et al.  Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.

[116]  Martin Zacharias,et al.  In silico prediction of binding sites on proteins. , 2010, Current medicinal chemistry.

[117]  A. Caflisch,et al.  Efficient electrostatic solvation model for protein‐fragment docking , 2001, Proteins.

[118]  R. DesJarlais.  Using computational techniques in fragment-based drug discovery. , 2011, Methods in enzymology.

[119]  Pierre Bruneau,et al.  A Database of Historically-Observed Chemical Replacements , 2007, J. Chem. Inf. Model..

[120]  Robert Kiss,et al.  Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..

[121]  Thomas Bäck,et al.  Substructure Mining Using Elaborate Chemical Representation , 2006, J. Chem. Inf. Model..

[122]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[123]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[124]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[125]  Luhua Lai,et al.  LigBuilder 2: A Practical de Novo Drug Design Approach , 2011, J. Chem. Inf. Model..

[126]  M Karplus,et al.  An automated method for dynamic ligand design , 1995, Proteins.

[127]  Eugen Lounkine,et al.  Formal concept analysis for the identification of molecular fragment combinations specific for active and highly potent compounds. , 2008, Journal of medicinal chemistry.

[128]  David E. Clark,et al.  Evolutionary algorithms in computer-aided molecular design , 1996, J. Comput. Aided Mol. Des..

[129]  Hugo O Villar,et al.  Computational techniques in fragment based drug discovery. , 2007, Current topics in medicinal chemistry.

[130]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[131]  B. Honig,et al.  On the nature of cavities on protein surfaces: Application to the identification of drug‐binding sites , 2006, Proteins.

[132]  Matthew Paul Gleeson,et al.  QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors , 2009, J. Chem. Inf. Model..

[133]  Alasdair T. R. Laurie,et al.  Methods for the prediction of protein-ligand binding sites for structure-based drug design and virtual ligand screening. , 2006, Current protein & peptide science.

[134]  Gergely M Makara,et al.  On sampling of fragment space. , 2007, Journal of medicinal chemistry.

[135]  Diana C. Roe,et al.  BUILDER v.2: Improving the chemistry of a de novo design strategy , 1995, J. Comput. Aided Mol. Des..

[136]  Yuri Pevzner,et al.  Fragment-Based Docking: Development of the CHARMMing Web User Interface as a Platform for Computer-Aided Drug Design , 2014, J. Chem. Inf. Model..

[137]  Jeffrey W. Peng,et al.  Theory and applications of NMR-based screening in pharmaceutical research. , 2004, Chemical reviews.

[138]  Peter Ertl,et al.  Cheminformatics Analysis of Organic Substituents: Identification of the Most Common Substituents, Calculation of Substituent Properties, and Automatic Identification of Drug-like Bioisosteric Groups , 2003, J. Chem. Inf. Comput. Sci..

[139]  N. Cohen,et al.  The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses. , 1993, Journal of medicinal chemistry.

[140]  Robert P. Sheridan.  Finding Multiactivity Substructures by Mining Databases of Drug-Like Compounds , 2003, J. Chem. Inf. Comput. Sci..

[141]  Wilfred F. van Gunsteren,et al.  Thermodynamic cycle integration by computer simulation as a tool for obtaining free energy differences in molecular chemistry , 1987, J. Comput. Aided Mol. Des..

[142]  Matthias Rarey,et al.  Exploring fragment spaces under multiple physicochemical constraints , 2007, J. Comput. Aided Mol. Des..

[143]  Yang Liu,et al.  Route Designer: A Retrosynthetic Analysis Tool Utilizing Automated Retrosynthetic Rule Generation , 2009, J. Chem. Inf. Model..

[144]  Mohane Selvaraj Coumar,et al.  Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity , 2014, Journal of Computer-Aided Molecular Design.

[145]  R. Cramer,et al.  Toward general methods of targeted library design: topomer shape similarity searching with diverse structures as queries. , 2000, Journal of medicinal chemistry.

[146]  A. McEwan,et al.  Discovery of novel pneumococcal surface antigen A (PsaA) inhibitors using a fragment-based drug design approach. , 2015, ACS chemical biology.

[147]  Michal Vieth,et al.  Structural Fragments in Marketed Oral Drugs , 2006 .

[148]  Lorenz M Mayr,et al.  Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.

[149]  Dima Kozakov,et al.  Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase , 2009, J. Comput. Aided Mol. Des..

[150]  Regine Bohacek,et al.  Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a de Novo Design Method Incorporating Combinatorial Growth , 1994 .

[151]  Brett A Tounge,et al.  Ligand efficiency and fragment-based drug discovery. , 2009, Drug discovery today.

[152]  Dora M Schnur,et al.  Are target-family-privileged substructures truly privileged? , 2006, Journal of medicinal chemistry.

[153]  G. Petsko,et al.  Multiple solvent crystal structures: probing binding sites, plasticity and hydration. , 2006, Journal of molecular biology.

[154]  Aurélien Grosdidier,et al.  Docking, virtual high throughput screening and in silico fragment-based drug design , 2009, Journal of cellular and molecular medicine.

[155]  Wilfred F van Gunsteren,et al.  Free energies of binding of polychlorinated biphenyls to the estrogen receptor from a single simulation , 2003, Proteins.

[156]  David Lou,et al.  FOG: Fragment Optimized Growth Algorithm for the de Novo Generation of Molecules Occupying Druglike Chemical Space , 2009, J. Chem. Inf. Model..

[157]  Tomas Åkerud,et al.  Discovery of a novel pyrazole series of group X secreted phospholipase A2 inhibitor (sPLA2X) via fragment based virtual screening. , 2014, Bioorganic & medicinal chemistry letters.

[158]  Valerie J. Gillet,et al.  SPROUT: Recent developments in the de novo design of molecules , 1994, J. Chem. Inf. Comput. Sci..

[159]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[160]  Ya-jun Guo,et al.  Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[161]  William L. Jorgensen,et al.  FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006 .

[162]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[163]  Kerim Babaoglu,et al.  Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.

[164]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[165]  R. Abagyan,et al.  Flexible ligand docking to multiple receptor conformations: a practical alternative. , 2008, Current opinion in structural biology.

[166]  Edward R Zartler,et al.  Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.

[167]  Matthias Rarey,et al.  Feature trees: A new molecular similarity measure based on tree matching , 1998, J. Comput. Aided Mol. Des..

[168]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[169]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[170]  Eugene I. Shakhnovich,et al.  SMOG : DE NOVO DESIGN METHOD BASED ON SIMPLE, FAST, AND ACCURATE FREE ENERGY ESTIMATES. 2. CASE STUDIES IN MOLECULAR DESIGN , 1997 .

[171]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature reviews. Drug discovery.

[172]  Rafael Gozalbes,et al.  Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. , 2010, Current medicinal chemistry.

[173]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[174]  Robert P. Sheridan,et al.  The Most Common Chemical Replacements in Drug-Like Compounds , 2002, J. Chem. Inf. Comput. Sci..

[175]  G. Schneider,et al.  Concepts and applications of "natural computing" techniques in de novo drug and peptide design. , 2010, Current pharmaceutical design.